Drug Profile
Research programme: antibody therapeutics - Biotecnol
Alternative Names: CAB051; IR051; IR052; Tb 434; Tb 535Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Biotecnol SA
- Developer Biotecnol Inc.
- Class Antibodies
- Mechanism of Action CD3 antigen inhibitors; ERBB 2 receptor antagonists; Signal transducing adaptor protein inhibitors; Wnt signalling pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastric cancer; Malignant melanoma; Mesothelioma; Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for research development in Mesothelioma in Portugal (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Portugal (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for research development in Gastric-cancer in Portugal (Parenteral)